Clinuvel Pharmaceuticals reported findings from study CUV151 at Salford Royal Hospital, Manchester. The study evaluated afamelanotide's DNA repair capability in UV-exposed individuals with fair skin.

Results demonstrated a reduction in UV-induced gene expression changes, from 625 to 183 differentially expressed genes post-treatment, indicating a 3.4-fold decrease.

Dennis Wright, the firm's chief scientific officer, highlighted afamelanotide's consistent support in repairing UV-damaged DNA and potentially mitigating oxidative and inflammatory responses post-UV exposure.

The findings underscore afamelanotide's potential in protecting against solar damage.